Technology Transfer

BATgal embryo


Timely Technology Transfer

Is vital to any thriving area of research, and we are vigilant for opportunities to exploit and translate our research for patient and economic benefit. We work closely with Medical Research Council Technology who are responsible for the protection development and commercialisation of intellectual property and research arising from MRC Units.







 

Over recent years we have had a number of successes:

  • James Sharpe (a previous Career-Track Scientist at the HGU) developed the novel and field - leading imaging technology Optical Projection Tomography (OPT), James Sharpe This was patented and, with funding from MRC Technology (commercial funds), Scottish Enterprise and the MRC Human Genetics Unit, the technology is now being commercialised Bioptonics.
  • Scientists have been in receipt of MRC Technology Development Gap Fund awards with the aim of taking areas of research to the point where it is suitable for industry exploitation. This includes a current project to develop new treatments for Systemic Lupus Erythematosus lead by Dr Andrew Jackson.

A number of antibodies have been developed and are now available commercially, including:

  • Professor Veronica van Heyningen has contributed 4 PAX-6 hybridomas and a number of monoclonal antibodies which are directed to the His-tag used in protein expression.
  • Professor Howard Cooke has interacted with Oxford University to develop monoclonal antibodies which have recently been licensed to Serotec for commercial sale.
  • Mouse Atlas Programme (joint Programme Leaders: Professor Richard Baldock and Dr Duncan Davidson) - the CD-Rom of the mouse gene expression database was licensed to Genentech. This is continuing to be developed as a tool for developmental biologist and is made available free. A number of patents have been filed including: WO2007141580.

It is worthy of note that over a number of years our students have been highly successful in the Biotechnology Yes Competition and we hope that this will continue.